Low-intensity therapy cures over 40 % of children with rapid Flow-MRD responding ALL: the ALL-MB 2008 trial results
- Authors: Popov A.1, Henze G.2, Roumiantseva Y.1, Budanov O.1,3, Belevtsev M.3, Verzhbitskaya T.4,5, Boyakova E.6, Movchan L.3, Tsaur G.4,5, Fadeeva M.1, Lagoyko S.1, Zharikova L.1, Myakova N.1, Litvinov D.1, Khlebnikova O.4,5, Streneva O.4,5, Stolyarova E.3, Ponomareva N.7, Novichkova G.1, Fechina L.4,5, Aleinikova O.3, Karachunskiy A.1
-
Affiliations:
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
- Charité – Universitätsmedizin Berlin
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
- Regional Children’s Hospital
- Research Institute of Medical Cell Technologies
- Moscow City Blood Center named after O. K. Gavrilov
- Republican Children’s Hospital
- Issue: Vol 21, No 2 (2022)
- Pages: 95-104
- Section: ORIGINAL ARTICLES
- Submitted: 24.06.2022
- Accepted: 24.06.2022
- Published: 08.07.2025
- URL: https://hemoncim.com/jour/article/view/621
- DOI: https://doi.org/10.24287/1726-1708-2022-21-2-95-104
- ID: 621
Cite item
Full Text
Abstract
Serious side effects occur during therapy for childhood acute lymphoblastic leukemia (ALL), and survivors can experience long-term consequences. This study aimed at identifying patients who can be successfully treated with low treatment intensity combining clinical parameters and minimal residual disease (MRD) measurements. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. ALL-MB studies used reduced-intensity therapy from the beginning, for standard risk (SR) patients no cyclophosphamide, a very low daunorubicin dose, no high dose of methotrexate, no cranial irradiation. In the ALL-MB 2008 study, 1702 children (49.1 % of all patients) were classified as SR due to favorable initial characteristics. These included 295 patients treated in institutions who took part in a pilot study on MRD measurement using flow cytometry on day 15 and/or at the end of induction (EOI). The most suitable time point for MRD measurement was EOI with threshold 0.1% in 90.5 % of the patients with excellent results: event-free survival of 95 % and overall survival of 97 %, that identified the large proportion of patients (more than 40 % of all ALL patients). The outcome of children with slower MRD response was significantly worse. Initial SR characteristics plus one single MRD measurement at EOI identify more than 40 % of all children with ALL who can be successfully treated with low-intensity regimens as used in the MB protocols.
About the authors
A. Popov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Author for correspondence.
Email: uralcytometry@gmail.com
ORCID iD: 0000-0002-0889-6986
Alexander M. Popov, MD, PhD, head of Leukemia immunophenotyping laboratory1 Sam
ory Mashela St., Moscow 117997
Russian FederationG. Henze
Charité – Universitätsmedizin Berlin
Department of Pediatric Oncology Hematology
Berlin
GermanyYu. Roumiantseva
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0001-9670-3728
Moscow
Russian FederationO. Budanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation; Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
ORCID iD: 0000-0003-3232-2322
Moscow, Russian Federation
Borovlyany, Minsk District, Belarus
Russian FederationM. Belevtsev
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Borovlyany, Minsk District
BelarusT. Verzhbitskaya
Regional Children’s Hospital; Research Institute of Medical Cell Technologies
ORCID iD: 0000-0001-9329-1828
Ekaterinburg
Russian FederationE. Boyakova
Moscow City Blood Center named after O. K. Gavrilov
Moscow
Russian FederationL. Movchan
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Borovlyany, Minsk District, Belarus
BelarusG. Tsaur
Regional Children’s Hospital; Research Institute of Medical Cell Technologies
ORCID iD: 0000-0002-9881-6221
Ekaterinburg
Russian FederationM. Fadeeva
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Moscow
Russian FederationS. Lagoyko
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-3793-104X
Moscow
Russian FederationL. Zharikova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-1105-8676
Moscow
Russian FederationN. Myakova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-4779-1896
Moscow
Russian FederationD. Litvinov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-7461-0050
Moscow
Russian FederationO. Khlebnikova
Regional Children’s Hospital; Research Institute of Medical Cell Technologies
Ekaterinburg
Russian FederationO. Streneva
Regional Children’s Hospital; Research Institute of Medical Cell Technologies
Ekaterinburg
Russian FederationE. Stolyarova
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Borovlyany, Minsk District
BelarusN. Ponomareva
Republican Children’s Hospital
ORCID iD: 0000-0002-6499-0977
Moscow
Russian FederationG. Novichkova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-2322-5734
Moscow
Russian FederationL. Fechina
Regional Children’s Hospital; Research Institute of Medical Cell Technologies
ORCID iD: 0000-0002-1885-3912
Ekaterinburg
Russian FederationO. Aleinikova
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Borovlyany, Minsk District
BelarusA. Karachunskiy
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Moscow
Russian FederationReferences
Supplementary files
